Cutaneous T-cell lymphoma: Biologic targets for therapy

Current Hematologic Malignancy Reports

Volumn 2, Issue 4, 2007, Pages 272-277

  Choi, Jaehyuk ^b   Foss, Francine ^a  

^a YALE CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BELINOSTAT; BEXAROTENE; CARMUSTINE; CHLORMETHINE; DENILEUKIN DIFTITOX; DEPSIPEPTIDE; FORODESINE; GAMMA INTERFERON; GUANINE ARABINOSIDE; HISTONE DEACETYLASE INHIBITOR; INTERFERON; LBH 584; RHOMIDEPSIN; SGN 30; UNCLASSIFIED DRUG; VORINOSTAT; ZANOLIMUMAB;

CANCER EPIDEMIOLOGY; CELL ACTIVATION; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; EPIGENETICS; HEREDITY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; PHENOTYPE; PUVA; REVIEW; T LYMPHOCYTE; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DIPHTHERIA TOXIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOMA, T-CELL, CUTANEOUS; NEOPLASM PROTEINS; PHOTOPHERESIS; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE;

EID: 38349068645     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0037-8     Document Type: Review

References (41)

1. Willemze R, Jaffe ES, Burg G, et al.: WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785. Outlines the staging system for cutaneous lymphomas.
2. Girardi M, Heald PW, Wilson LD: The pathogenesis of mycosis fungoides. N Engl J Med 2004, 350:1978-1988. Excellent review of the immunologic basis and pathogenesis of cutaneous T-cell lymphomas.
3. Kim EJ, Hess S, Richardson SK, et al.: Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005, 115:798-812.
4. Mao X, Lillington D, Scarisbrick JJ, et al.: Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol 2002, 147:464-475.
5. Frankfurt O, Rosen ST: Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 2004, 16:553-563.
6. Zackheim HS, Kashani-Sabet M, Amin S: Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998, 134:949-954.
7. Whittaker SJ, Foss FM: Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007, 33:146-160. Excellent overview of existing treatment strategies for cutaneous T-cell lymphomas.
8. Weichenthal M, Schwarz T: Phototherapy: How does UV work? Photodermatol Photoimmunol Photomed 2005, 21:260-266.
9. Jones GW, Hoppe RT, Glatstein E: Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1057-1076.
10. Schramm VL: Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochim Biophys Acta 2002, 1587:107-117.
11. Balakrishnan K, Nimmanapalli R, Ravandi F, et al.: Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006, 108:2392-2398.
12. Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001: 19:376-388.
13. Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005, 106:454-457.
14. Druker BJ, Guilhot F, O'Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
15. McGregor JM, Crook T, Fraser-Andrews EA, et al.: Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest Dermatol 1999, 112:317-321.
16. Kari L, Loboda A, Nebozhyn M, et al.: Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003, 197:1477-1488.
17. Scarisbrick JJ, Mitchell TJ, Calonje E, et al.: Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003, 121:894-901.
18. Scarisbrick JJ, Woolford AJ, Calonje E, et al.: Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sézary syndrome. J Invest Dermatol 2002, 118:493-499.
19. van Doorn R, Zoutman WH, Dijkman R , et al.: Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005, 23:3886-3896.
20. Marks PA: The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 2004, 3:534-535.
21. Duvic M, Talpur R, Ni X, et al.: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
22. Berger CL, Hanlon D, Kanada D, et al.: The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002, 99:2929-2939.
23. Edelson RL: Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci 2001, 941:1-11.
24. Yamanaka K, Clark R, Rich B, et al.: Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006, 107:2440-2445.
25. Ortonne N, Huet D, Gaudez C, et al.: Significance of circulating T-cell clones in Sézary syndrome. Blood 2006, 107:4030-4038.
26. Rook AH, Kuzel TM, Olsen EA: Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003, 17:1435-1448, ix.
27. Hoppe RT, Medeiros LJ, Warnke RA, et al.: CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995, 32:448-453.
28. Wysocka M, Benoit BM, Newton S, et al.: Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004, 104:4142-4149.
29. Yawalkar N, Ferenczi K, Jones DA, et al.: Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003, 102:4059-4066.
30. Axelrod PI, Lorber B, Vonderheid EC: Infections complicating mycosis fungoides and Sézary syndrome. JAMA 1992, 267:1354- 1358.
31. Mao X, Orchard G, Lillington DM, et al.: BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 2004, 151:546-556.
32. Zic JA: The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003, 16:337-346.
33. Berger CL, Xu AL, Hanlon D, et al.: Induction of human tumor-loaded dendritic cells. Int J Cancer 2001, 91:438-447.
34. Moor AC, Schmitt IM, Beijersbergen van Henegouwen GM, et al.: Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results. J Photochem Photobiol B 1995, 29:193-198.
35. Perez MI, Edelson RL, John L, et al.: Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells). Yale J Biol Med 1989, 62:595-609.
36. Berger CL, Wang N, Christensen I, et al.: The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 1996, 107:392-397.
37. Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987, 316:297-303.
38. Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
39. Takaoka A, Hayakawa S, Yanai H, et al.: Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516-523.
40. Rook AH, Wood GS, Yoo EK, et al.: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999, 94:902-908.
41. Suchin KR, Cucchiara AJ, Gottleib SL, et al.: Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002, 138:1054-1060.